Research Topics
| Susan GoodinSummaryAffiliation: New Jersey Country: USA Publications
| Collaborators
|
Detail Information
Publications
Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancerSusan Goodin
Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, USA
Am J Health Syst Pharm 65:2017-26. 2008..The pharmacology, pharmacokinetics, clinical efficacy, safety, dosage, and administration of ixabepilone in patients with metastatic breast cancer are examined...- Development of monoclonal antibodies for the treatment of colorectal cancerSusan Goodin
Division of Pharmaceutical Sciences, The Cancer Institute of New Jersey, and University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 195 Little AlbanyStreet, New Brunswick, NJ 08901, USA
Am J Health Syst Pharm 65:S3-7; quiz S22-4. 2008.... - Oral chemotherapeutic agents: understanding mechanisms of action and drug interactionsSusan Goodin
University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 08901, USA
Am J Health Syst Pharm 64:S15-24. 2007..The mechanisms of action and drug interactions of oral chemotherapeutic agents are reviewed... - Selecting an anticoagulant for recurrent venous thromboembolism in cancerSusan Goodin
Division of Pharmaceutical Sciences, The Cancer Institute of New Jersey, USA
Am J Health Syst Pharm 62:S10-3. 2005.... - Clinical and biological activity of soy protein powder supplementation in healthy male volunteersSusan Goodin
Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08903 2681, USA
Cancer Epidemiol Biomarkers Prev 16:829-33. 2007.... - Current issues associated with oral chemotherapy: a roundtable discussionSusan Goodin
Medical Oncology, The Cancer Institute of New Jersey, 195 Little Albany Street, Room 2012, New Brunswick, NJ 08903-2681, USA
Am J Health Syst Pharm 64:S33-5. 2007 - NSAIDs for the chemoprevention of oral cancer: promise or pessimism?: Commentary re J. L. Mulshine et al., randomized, double-blind, placebo-controlled, phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakiSusan Goodin
Department of Medicine, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA
Clin Cancer Res 10:1561-4. 2004 - Erlotinib: optimizing therapy with predictors of response?Susan Goodin
Pharmaceutical Sciences, The Cancer Institute of New Jersey and Division of Medical Oncology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ 08903-2681, USA
Clin Cancer Res 12:2961-3. 2006 - Novel cytotoxic agents: epothilonesSusan Goodin
The Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
Am J Health Syst Pharm 65:S10-5. 2008..The epothilones are effective antitumor medications for patients with breast cancer, including patients who have been previously treated with or are resistant to anthracyclines or the taxanes... - Progress in the development of monoclonal antibody therapies for colorectal cancer. IntroductionSusan Goodin
Division of Pharmaceutical Sciences, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 195 Little AlbanyStreet, New Brunswick, NJ 08901, USA
Am J Health Syst Pharm 65:S2. 2008 - 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profileSusan Goodin
The Cancer Institute of New Jersey, New Brunswick 08903, USA
Oncologist 7:424-36. 2002..Clinicians are encouraged to evaluate patients on an individual basis when choosing which 5-HT(3)-receptor antagonist to prescribe... - A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancerSusan Goodin
Department of Medicine, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA
Cancer Chemother Pharmacol 56:199-204. 2005..The combination of docetaxel and vinorelbine with filgrastim was well tolerated and active against HRPC in patients with or without prior chemotherapy... - Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancerSusan Goodin
Department of Medicine, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, Piscataway, USA
J Clin Oncol 23:3352-7. 2005..Accrual to national phase III studies in early disease is now critical and should be strongly encouraged to determine the ability of early chemotherapy to improve survival... - Ixabepilone, a new treatment option for metastatic breast cancerDeborah L Toppmeyer
Department of Medicine, Cancer Institute of New Jersey, New Brunswick, 08901 USA
Am J Clin Oncol 33:516-21. 2010..Further clinical studies are evaluating the combination of ixabepilone with targeted agents such as trastuzumab or bevacizumab to further define the role of this novel agent in the treatment of MBC... - A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancerKamakshi Rao
The Dean and Betty Gallo Prostate Cancer Center at The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA
Prostate 62:115-22. 2005..CONCLUSIONS: This first study evaluated the efficacy and safety of imatinib in patients with early androgen sensitive prostate cancer following local therapy. As a single agent at this dosing, imatinib had limited biochemical activity... - Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survivalJennifer Nishioka
The Cancer Institute of New Jersey, UMDNJ Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, New Jersey 08901, US
J Oncol Pharm Pract 13:85-97. 2007.... - Tubulin-targeting agentsWilliam N Hait
UMDNJ/Robert Wood Johnson Medical School, Department of Medicine, New Brunswick, NJ 08901-1914, USA
Cancer Chemother Biol Response Modif 21:41-67. 2003 - Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignanciesMark Stein
Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08901, USA
Prostate 70:1388-94. 2010.... - Epothilones: mechanism of action and biologic activitySusan Goodin
Department of Medicine, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, USA
J Clin Oncol 22:2015-25. 2004..The results suggest that these compounds have a broad range of antitumor activity at doses and schedules associated with tolerable side effects... - Antiemetic care for patients with breast cancer: focus on drug interactions and safety concernsAngela Georgy
Pharmaceutical Industry Fellowship Institute, School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA
Am J Health Syst Pharm 64:2227-36. 2007..The drug interactions and adverse events that should be considered when individualizing antiemetic therapy for patients undergoing treatment for breast cancer are reviewed... - Tubulin-targeting agentsWilliam N Hait
UMDNJ/Robert Wood Johnson Medical School, Department of Medicine, The Cancer Institute of New Jersey, New Brunswick 08901-1914, USA
Cancer Chemother Biol Response Modif 22:35-59. 2005 - Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumorsAntoinette R Tan
The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA
Clin Cancer Res 12:6517-22. 2006..The purpose of this trial was to evaluate the pharmacokinetics of cetuximab given as a single dose followed by weekly fixed repeated dosing in patients with solid tumors... - Overcoming drug resistance in patients with metastatic breast cancerSerena T Wong
Department of Medicine, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08903, USA
Pharmacotherapy 29:954-65. 2009.... - Management of venous thromboembolism and the potential to impact overall survival in patients with cancerBiren Saraiya
Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA
Pharmacotherapy 29:1344-56. 2009..Aggressive VTE management and strategies are critical to improving survival in patients with cancer and VTE... - A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancyDeborah L Toppmeyer
Departments of Medicine and Pharmacology, Robert-Wood Johnson Medical School and The Cancer Institute, University of Medicine and Dentistry, New Brunswick, New Jersey, USA
Med Sci Monit 9:PI99-104. 2003..Additional studies are necessary to determine whether this combination is more effective in controlling tumor progression than paclitaxel alone... - A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasmaMurugesan K Gounder
The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ, 08901, USA
Biomed Chromatogr 26:650-4. 2012..The method was successfully applied to characterize the pharmacokinetics profile of 2-DG in patients with advanced solid tumors. Copyright © 2011 John Wiley & Sons, Ltd... - Full costs of dispensing and administering fluorouracil chemotherapy for outpatients: A microcosting studyDong Churl Suh
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854 8020, USA
Res Social Adm Pharm 6:246-56. 2010.... - Tubulin-targeting agentsWilliam N Hait
UMDNJ/Robert Wood Johnson Medical School, Departments of Medicine and Pharmacology, Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ, USA
Cancer Chemother Biol Response Modif 20:71-97. 2002 - Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignanciesRobert S DiPaola
Department of Medicine, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
Med Sci Monit 9:PI5-11. 2003..Administration of gemcitabine and paclitaxel followed by carboplatin was well tolerated and clinically active. GCP should be compared to other combination regimens under investigation for the treatment of TCC... - Abiraterone in prostate cancer: a new angle to an old problemMark N Stein
Authors Affiliations The Cancer Institute of New Jersey, New Brunswick University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey
Clin Cancer Res 18:1848-54. 2012..Clin Cancer Res; 18(7); 1848-54. ©2012 AACR... - State-of-the-art treatment of metastatic hormone-refractory prostate cancerSusan Goodin
The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA
Oncologist 7:360-70. 2002..Evaluation and incorporation of these agents into existing treatment regimens will guide us in the development of more active regimens in the treatment of HRPC... - Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinasesPatrick J Medina
College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
Clin Ther 30:1426-47. 2008.... - Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasoneCeleste Lindley
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7360, USA
Am J Clin Oncol 28:270-6. 2005.... - Drug-drug interactions in oncology: why are they important and can they be minimized?Peter Blower
Biophar Consulting, Poole House, Great Yeldham, Halstead, Essex CO9 4HP, UK
Crit Rev Oncol Hematol 55:117-42. 2005..This review considers the basic principles of drug-drug interactions, and presents specific examples that are relevant to oncology... - Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastasesTianling Chen
Department of Clinical Pharmacology, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA
J Clin Pharmacol 42:1228-36. 2002..The antiresorptive effects were evident within 1 day postdose and were maintained over 28 days across all dose levels, supporting monthly dosing with 4 mg zoledronic acid... - Cancer-treatment-induced bone loss, part 2Laura Boehnke Michaud
The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Am J Health Syst Pharm 63:534-46. 2006..The pathophysiology, frequency, sequelae, diagnosis, and treatment of cancer-treatment-induced bone loss (CTIBL) are discussed... - Cancer-treatment-induced bone loss, part 1Laura Boehnke Michaud
The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Am J Health Syst Pharm 63:419-30. 2006..The pathophysiology, frequency, sequelae, diagnosis, and treatment of cancer-treatment-induced bone loss (CTIBL) are discussed... - Conceptualization of disease timeline predicts posttreatment distress in breast cancer patientsCarolyn Rabin
Department of Psychiatry and Human Behavior, Brown Medical School and The Miriam Hospital, Providence, RI 02903, USA
Health Psychol 23:407-12. 2004..The way patients conceptualize their illness appears to be more influential in determining levels of posttreatment distress than objective indicators of the likelihood of recurrence... - Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostateParvesh Kumar
Department of Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, 90033 0804, USA
J Clin Oncol 22:1909-15. 2004..A phase I trial was conducted to determine the maximally tolerated dose (MTD) of concurrent weekly docetaxel and three-dimensional conformal radiation therapy (3-D CRT) in unfavorable localized adenocarcinoma of the prostate...